Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25Deepening responses observed over time in ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

We are delighted to welcome Kristen and Nancy to our Board of Directors,” said Tom King, Executive Chairman of Achieve’s Board of Directors. “Their wealth of knowledge and experience in strategic ...

The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall expenditure.

Alpha- and beta-blockers reduce oxidative stress and inflammation caused by aircraft noise but fail to prevent hypertension, ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

Doctors used a tool to look deep into her ear, a procedure called an otoscopy, and noted the ear canal was congested and ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Healthcare professionals may recommend ginger for nausea relief, especially for motion sickness, during pregnancy, and when ...

Muscle twitching is a significant cause for concern when accompanied by other neurological symptoms such as muscle weakness, ...